Sign In
Buy ANIX
$3.42
-0.140 (-3.93%)
At Close: Jul 31, 2026
Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial
08:30am, Tuesday, 07'th Oct 2025
Final Clinical Visit Marks Major Milestone in First-in-Human Evaluation of Breast Cancer Vaccine Comprehensive Immune Response and Safety Data to Be Presented at the San Antonio Breast Cancer Symposiu
Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and Prevention Comprehensive Results, Supported by U.S. Department of Defense Funding, to Inform FDA Di
3 Under-the-Radar Biotechs Under $5 That Could Soar 200%
06:45pm, Tuesday, 09'th Sep 2025
Investing in biotechnology stocks is typically reserved for speculative investors. For starters, many of these companies are clinical or pre-clinical stage companies.
Continue to observe a positive safety profile—no dose limiting toxicities, cytokine release syndrome or immune effector cell-associated neurotoxicity SAN JOSE, Calif. , Sept. 8, 2025 /PRNewswire/ --
Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
08:54am, Tuesday, 02'nd Sep 2025
SAN JOSE, Calif. , Sept. 2, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an
Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
09:13am, Monday, 25'th Aug 2025
SAN JOSE, Calif. , Aug. 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today a
Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer Vaccine Expands global intellectual property coverage in markets with high breast cancer incidence New patent will pr
Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
09:00am, Monday, 18'th Aug 2025
Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif. , Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology
08:05am, Tuesday, 12'th Aug 2025
Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif. , Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: AN
Dr. Wenham is Principal investigator on Anixa's CAR-T therapy for Ovarian Cancer SAN JOSE, Calif. , Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a bi
Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial
08:45am, Monday, 04'th Aug 2025
Progress Follows Positive Immune Response Observed in Phase 1 Study SAN JOSE, Calif. , Aug. 4, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology
Patent Strengthens International Protection for First-of-Its-Kind Immunopreventive Platform Expands Global IP Coverage in Markets with High Incidence of Breast Cancer SAN JOSE, Calif. , July 30, 2025
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?
10:41am, Friday, 25'th Jul 2025
Here is how ANIXA BIOSCIENCES INC (ANIX) and Mind Medicine (MindMed) Inc. (MNMD) have performed compared to their sector so far this year.
Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s
08:00am, Thursday, 24'th Jul 2025
Patent Expands Immunogenic Coverage of α-Lactalbumin-Based Vaccine Platform Technology Addresses Substantial Unmet Need in Preventive Oncology with Multi-Billion Dollar Market Potential SAN JOSE, Cal
Anixa Biosciences: Oncology Platform With Asymmetric Upside
03:49pm, Tuesday, 15'th Jul 2025
ANIX has a dual-platform approach. It has an FSHR‑targeted CAR‑T program for ovarian cancer and an α‑lactalbumin breast cancer vaccine. Their Phase 1 CAR‑T showed reasonable safety, as one
